Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Stress-related hormones modulate cytokine expression in the head kidney of gilthead seabream (Sparus aurata)

  • Castillo, Juan
  • Teles, Mariana|||0000-0001-5525-4049
  • Mackenzie, Simon|||0000-0003-1845-6826
  • Tort Bardolet, Lluís|||0000-0002-3907-722X
Neuro-endocrine and immune systems closely interact in fish, and their regulation is crucial for the maintenance of good health of cultured fish. We have used the seabream head kidney to study whether stress-related hormones can modulate the immune response. For this purpose, the effects of adrenaline, adrenocorticotropic hormone (ACTH) and cortisol on the expression of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and the anti-inflammatory cytokine TGF-β1 were determined by means of quantitative real-time PCR on isolated head kidney cells. ACTH (150 ng mL-1) caused an acute increase of TNF-α and IL-6 mRNA levels as well as an inhibition of IL-1β expression. The expression of the anti-inflammatory cytokine TGF-β1 was also increased, although in a lower extent. Adrenaline (1 μM) early effects were only clear inhibiting IL-1β expression but not TNF-α, IL-6 or TGF-β1 mRNA levels, while a longer exposure to the hormone inhibited all cytokines. Moreover, cortisol (50 and 100 ng mL-1) reduced the expression of all cytokines in a dose-dependent manner. Bacterial lipopolysaccharide (LPS) stimulated IL-1β expression and inhibited that of the anti-inflammatory TGF-β1, although it was ineffective on TNF-α and IL-6. In addition, adrenaline and cortisol decreased the LPS-stimulated IL-1β expression, further demonstrating their previously reported anti-inflammatory effects. The combination of ACTH and LPS, on the other hand, did not affect LPS-stimulated IL-1β expression but was effective increasing TNF-α expression. Taking all these results in consideration, we conclude that the expression of pro- and anti-inflammatory cytokines in the seabream head kidney is highly influenced by stress-related hormones, thus indicating an important role for the endocrine system in the modulation of the immune response in teleost fish.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma

  • Cappuyns, Sarah
  • Piqué-Gili, Marta
  • Esteban-Fabró, Roger
  • Philips, Gino
  • Balaseviciute, Ugne
  • Pinyol, Roser|||0000-0002-0288-6314
  • Gris-Oliver, Albert|||0000-0003-1802-9541
  • Vandecaveye, Vincent
  • Abril-Fornaguera, Jordi|||0000-0002-5871-4052
  • Montironi, Carla|||0000-0002-1453-2193
  • Bassaganyas, Laia|||0000-0002-4575-0214
  • Peix, Judit
  • Zeitlhoefler, Marcus
  • Mesropian, Agavni
  • Huguet Pradell, Júlia
  • Haber, Philipp K
  • Figueiredo, Igor
  • Ioannou, Giorgio
  • Gonzalez Kozlova, Edgar
  • D'Alessio, Antonio
  • Mohr, Raphael
  • Meyer, Tim
  • Lachenmayer, Anja|||0000-0002-5879-5737
  • Marquardt, Jens U
  • Reeves, Helen L.|||0000-0003-0359-9795
  • Edeline, Julien
  • Finkelmeier, Fabian
  • Trojan, Jorg
  • Galle, Peter R
  • Foerster, Friedrich
  • Mínguez Rosique, Beatriz|||0000-0002-7276-9666
  • Montal, Robert
  • Gnjatic, Sacha
  • Pinato, David James|||0000-0002-3529-0103
  • Heikenwälder, Mathias
  • Verslype, Chris
  • Van Cutsem, Eric|||0000-0002-6372-1230
  • Lambrechts, Diether
  • Villanueva, Augusto|||0000-0003-3585-3727
  • Dekervel, Jeroen
  • Llovet, Josep M.|||0000-0003-0547-2667
The combination of atezolizumab and bevacizumab (atezo+bev) is the current standard of care for advanced hepatocellular carcinoma (HCC), providing a median overall survival (OS) of 19.2 months. Here, we aim to uncover the underlying cellular processes driving clinical benefit vs. resistance to atezo+bev. We harnessed the power of single-cell RNA sequencing in advanced HCC to derive gene expression signatures recapitulating 21 cell phenotypes. These signatures were applied to 422 RNA-sequencing samples of patients with advanced HCC treated with atezo+bev (n = 317) vs. atezolizumab (n = 47) or sorafenib (n = 58) as comparators. We unveiled two distinct patterns of response to atezo+bev. First, an immune-mediated response characterised by the combined presence of CD8+ T effector cells and pro-inflammatory CXCL10+ macrophages, representing an immune-rich microenvironment. Second, a non-immune, angiogenesis-related response distinguishable by a reduced expression of the VEGF co-receptor neuropilin-1 (NRP1), a biomarker that specifically predicts improved OS upon atezo+bev vs. sorafenib (p = 0.039). Primary resistance was associated with an enrichment of immunosuppressive myeloid populations, namely CD14+ monocytes and TREM2+ macrophages, and Notch pathway activation. Based on these mechanistic insights we define " Immune-competent " and " Angiogenesis-driven " molecular subgroups, each associated with a significantly longer OS with atezo+bev vs. sorafenib (p of interaction = 0.027), and a " Resistant" subset. Our study unveils two distinct molecular subsets of clinical benefit to atezolizumab plus bevacizumab in advanced HCC (" Immune-competent" and " Angiogenesis-driven") as well as the main traits of primary resistance to this therapy, thus providing a molecular framework to stratify patients based on clinical outcome and guiding potential strategies to overcome resistance. Atezolizumab + bevacizumab (atezo+bev) is standard of care in advanced hepatocellular carcinoma (HCC), yet molecular determinants of clinical benefit to the combination remain unclear. This study harnesses the power of single-cell RNA sequencing, deriving gene expression signatures representing 21 cell subtypes in the advanced HCC microenvironment. By applying these signatures to RNA-sequencing samples, we reveal two distinct response patterns to atezo+bev and define molecular subgroups of patients (" Immune-competent" and " Angiogenesis-driven" vs. "Resistant") with differential clinical outcomes upon treatment with atezo+bev, pointing towards the role of immunosuppressive myeloid cell types and Notch pathway activation in primary resistance to atezo+bev. These results may help refine treatment strategies and improve outcomes for patients with advanced HCC, while also guiding future research aimed at overcoming resistance mechanisms.